S1 Guideline: Therapy of generalized pustular psoriasis
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner +17 more
wiley +1 more source
Inequality and determinants of access to phototherapy among patients with psoriasis in Thailand. [PDF]
Churee C +2 more
europepmc +1 more source
Phototherapy for Skin of Color in the Biologic Era: A Cross-Sectional Survey of Moroccan Dermatologists' Knowledge and Practice. [PDF]
Baghad B, Dahbi Skali H, Chiheb S.
europepmc +1 more source
The different face of skin‐rash induced by brentuximab vedotin
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri +11 more
wiley +1 more source
Prevalence of hypocalcemia in neonates receiving phototherapy: a systematic review and meta-analysis. [PDF]
Belayhun E +13 more
europepmc +1 more source
Summary Background and objectives The financial and time‐related burden of patients with vitiligo remains insufficiently studied. This study aimed to quantify out‐of‐pocket costs (OOPC) and time expenditure for vitiligo management and the associated sociodemographic, clinical, and behavioral factors in German‐speaking countries.
Christine Gasteiger +5 more
wiley +1 more source
Effect of irradiance and delivery configuration on phototherapy efficacy in preterm infants: a network meta-analysis and meta-regression of randomized trials. [PDF]
Talha M +9 more
europepmc +1 more source
Comparative effectiveness of different probiotics combined with phototherapy for neonatal hyperbilirubinemia: a retrospective, non-randomized cohort study. [PDF]
Li X +5 more
europepmc +1 more source
Ropeginterferon‐α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients
Summary Background and objectives Pegylated interferon‐α2a became the off‐label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non‐pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon‐α2b in MF/SS. Patients and methods We performed a retrospective multicenter analysis at
Stefanie Porkert +15 more
wiley +1 more source

